[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tia-transient-ischemic-attack\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tia-transient-ischemic-attack":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,75,119,152,178,205,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100624830","testing-the-effectiveness-of-a-novel-intervention-to-improve-medication-adherence-in-stroke-survivors-100624830",false,"NCT07414732","Testing the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors","The \"Savvy for Stroke Survivors\" Study: Testing a Novel Tool to Help Stroke Survivors Take Their Medication","Inclusion criteria:\n\n1. Participants must be between the ages of 18 years old and 99 years old at the time of consent.\n2. Self-reported primary diagnosis of stroke (ischemic or hemorrhagic) within the past 12 months, without structural, traumatic or secondary causes (including aneurysm, arteriovenous malformation, or tumor).\n3. Currently prescribed an antihypertensive regimen.\n4. Currently less than optimal adherence to medication, defined as a score \\\u003C25 on the Medication Adherence Report Scale (MARS-5).\n5. Cognitively able to manage medications independently, defined as a score of \\>4 on the Six-Item Screener (SIS) for cognitive impairment.\n6. Speaks English sufficiently to complete consent and study procedures.\n7. Has access to a phone that can receive text messages and is able to participate in scheduled phone-based follow-up assessments.\n8. Uses, or willing to start using, a single pharmacy chain for prescription refills and is willing to provide consent for the study team to contact the pharmacy to retrieve prescription refill data.\n9. Willing and able to provide informed consent.\n\nExclusion criteria:\n\n1. Prescribed a more than three scheduled daily medication doses.\n2. Prescribed a complex medication regimen requiring more than five additional oral medications per dose time.\n3. Diagnosed with secondary hypertension or other BP conditions not managed with standard oral antihypertensives.\n4. Has upper extremity impairments or other physical limitations that prevent safe use of the medication box or BP monitor.\n5. Lives in an environment where the medication organizer cannot be safely or consistently accessed, such as in temporary housing, shelters, or unstable living conditions.\n6. Diagnosed with moderate-to-severe cognitive impairment, dementia, or active psychiatric instability that precludes informed consent or reliable participation.\n7. Known allergy or contraindication to the materials used in the BP monitor or the medication box.\n8. Participation in another intervention trial targeting medication adherence or BP control.\n9. Planned relocation or anticipated unavailability for the 12-month study period.","ALL","18 Years","99 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to test if Savvy, a multimodal intervention (consisting of psychological exercises, a weekly pill organizer, and a text message reminder system) can improve medication adherence in stroke survivors.\n\nThe main questions it aims to answer are:\n\n* Can the Savvy tool improve medication adherence in stroke survivors compared to usual care?\n* Does the use of the Savvy tool lead to better blood pressure control after a stroke?\n\nThe investigators will compare the use of the Savvy intervention to a control group that receives usual care, including a package of educational materials.\n\nThe study consists of the following components:\n\n* Participants will receive the Savvy intervention or usual care. The intervention package consists of short psychological exercises over the phone, a weekly medication organizer to support daily medication intake, and text message reminders to take medication and refill the medication box. Participants in the control group will receive usual care, including educational materials about the importance of blood pressure and medication.\n* All participants will receive a free home blood pressure monitor and will be requested to measure their blood pressure at certain time points during the study.\n* Participants will be enrolled in the study for 6 months and will have virtual follow-up calls at 3 and 6 months.",[27,28,29,30],"Stroke","Intracerebral Haemorrhage","Ischemic Stroke","TIA (Transient Ischemic Attack)",[32,33,34,27,35],"Medication Adherence","Motivational Interviewing (MI)","Blood pressure","Secondary Prevention","RECRUITING","2026-05-19",{"date":39,"type":40},"2026-05-20","ACTUAL",{"date":42,"type":40},"2026-03-31",{"date":44,"type":21},"2027-04-30",{"name":46,"class":47},"Massachusetts General Hospital","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100640711","prospective-italian-validation-of-sms-in-patients-with-suspected-acute-stroke-100640711","NCT07601659","Prospective Italian Validation of SMS in Patients With Suspected Acute Stroke","Prospective Italian Multicenter Study for the Validation of the Stroke Mimics Score (SMS) in Patients With Suspected Acute Stroke","PIVA-SMS","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of presentation to the Emergency Department.\n* Presentation to the Emergency Department with a clinical suspicion of acute stroke, identified at nursing triage and\u002For through activation of the stroke pathway.\n* Presentation to the Emergency Department during the 6-month prospective enrollment period.\n* Feasibility of real-time collection of the data required to calculate the Stroke Mimics Score (SMS), including:\n\nage, systolic blood pressure, presence\u002Fabsence of seizure at onset, presence\u002Fabsence of headache at onset, presence\u002Fabsence of confusion at onset, presence\u002Fabsence of syncope at onset, presence\u002Fabsence of isolated sensory deficit, presence\u002Fabsence of motor deficit, history of coronary artery disease, history of prior stroke or transient ischemic attack (TIA).\n\n* Availability of a final hospital discharge diagnosis at the end of hospitalization or Emergency Department observation.\n* Signed informed consent from the patient or caregiver. If the patient is unconscious upon arrival at the Emergency Department, deferred consent will be applied.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Inability to fully collect the data required to calculate the Stroke Mimics Score (SMS).\n* Absence of a clearly defined final hospital discharge diagnosis.\n* Voluntary discharge, transfer, or death before completion of the diagnostic workup, in the absence of a reliable diagnosis.\n* Repeated Emergency Department visits for the same clinical event (only the first visit will be considered).",{"count":58,"type":21},1000,"OBSERVATIONAL","The overall objective of the study is to prospectively validate the diagnostic accuracy of the Stroke Mimics Score (SMS). This score is calculated using information collected at the time of the patient's arrival in the Emergency Department (triage) and may assist clinicians in distinguishing between:\n\n1. cerebrovascular events (ischemic stroke, intracerebral hemorrhage, and transient ischemic attack \\[TIA\\]),\n2. stroke mimics (i.e., conditions that present with stroke-like symptoms but without actual infarction of brain tissue).\n\nIn addition, the study aims to compare its results with other existing tools and to evaluate its performance across different patient groups.\n\nSpecifically, the present research seeks to generate data on the reliability of the SMS tool in providing an accurate diagnosis.",[62,63,64,30,27],"Cerebrovascular Event","Acute Ischemic Stroke","Intracerebral Hemorrhage","NOT_YET_RECRUITING","2026-05-15",{"date":68,"type":40},"2026-05-22",{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2027-06-01",{"name":74,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100635761","clinical-impact-of-using-improve-to-select-patients-for-carotid-revascularisation-100635761","NCT07556887","Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation","Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","IMPROVE","Inclusion Criteria:\n\n* Mentally competent\n* 18 years or older\n* Recent (\\\u003C30 days) stroke (modified Rankin scale ≤3) or TIA\n* Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria\n* Life expectancy \\>5 years\n* Patient and stenosis are suitable for carotid revascularisation\n* Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation\n\nExclusion Criteria:\n\n* Cardiac source of embolism\n* Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy.\n* MRI contra-indications\n* Pregnancy",{"count":84,"type":21},613,[24],"Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.",[88,89,90,91,92,27,93,30,94,95],"Carotid Artery Stenosis Symptomatic","Ischemic Cerebral Infarction","Stroke Ischemic","Atheroscleroses","Stroke (CVA) or TIA","Intraplaque Hemorrhage","Atherosclerosis Cerebral Infarction","Carotid Arteriosclerosis",[97,98,29,99,100,101,102,103,104,105,106,107,108,109,110],"Carotid Artery Stenosis","Transient Ischemic Attack","Atherosclerosis","Plaque Rupture","Revascularisation","Carotid Endarterectomy","Carotid Artery Stenting","Magnetic Resonance Imaging","Stroke Risk Prediction","Intraplaque hemorrhage","Clinical Decision Support","Randomized Controlled Mulitcentre Trial","Cost-Effectiveness Analysis","Optimal Medical Therapy","2026-05-12",{"date":66,"type":40},{"date":42,"type":40},{"date":115,"type":21},"2031-08-31",{"name":117,"class":47},"Maastricht University Medical Center",10,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100625387","prospective-registry-of-vertigo-due-to-vertebrobasilar-transient-attacks-100625387","NCT07421973","Prospective Registry of Vertigo Due to Vertebrobasilar Transient Attacks.","The UTRAVERA: a Multicenter Prospective Observational Investigation on Vertigo and Dizziness Due to Vertebrobasilar Transient Neurological Attacks - Diagnoses, Clinical Features, Treatment Responses, and Prognostic Factors.","UTRAVERA","Inclusion Criteria:\n\n* Episodic acute vertigo, dizziness or unsteadiness transient or in evolution, therefore, lasting \\\u003C24 h\n* Such an episode may be isolated or associated with one or more of the following:\n\n  1. focal central neurological symptoms or severe postural instability;\n  2. new-onset, moderate-to-severe craniocervical pain; or\n  3. symptoms that are not better accounted for by another disease or disorder.\n\nExclusion Criteria:\n\n* Patients who present with findings of acute hemorrhage or ischemia on the cranial magnetic resonance imaging (MRI), including diffusion-weighted MRI (DWI-MRI) at recruitment;\n* Patients who also fulfill the diagnostic criteria for other neurotological diseases that may present acute or recurrent transient dizziness\u002FVertigo (Unilateral Vestibulopathy; benign paroxysmal positional vertigo; Meniére's disease; Vestibular Migraine; Vestibular Paroxysmia; Persistente Postural-Perceptual Dizziness; and Postural Hypotension;\n* Patients whose symptoms last more than 24 hours or who have evidence of sequelae during follow-up;\n* Patients with contraindications to any of the therapeutic options proposed by this study method;\n* Patients who have other symptoms during the follow-up that suggest another etiology of dizziness or vertigo;\n* Patients who do not complete the entire evaluation;\n* Patients who refuse to sign the informed consent form.",{"count":128,"type":21},400,"Vertigo and dizziness are common neurological complaints in the emergency department and may represent a wide spectrum of etiologies, including vertebrobasilar transient neurological attacks (VB-TNAs). Distinguishing VB-TNAs, particularly vertebrobasilar transient ischemic attacks (VB-TIAs), from migraine-like and other non-vascular conditions is often challenging at first presentation due to the absence of specific biomarkers and overlapping clinical features. The UTRAVERA study is a multicenter, prospective, observational investigation designed to characterize the clinical features of patients presenting with acute transient vertigo or dizziness suspected to be VB-TNAs. The study will also evaluate diagnostic evolution over time, treatment responses, and prognostic factors associated with clinical outcomes.",[131,132,30,133],"Vertigo","Dizziness","Transient Neurologic Symptoms",[135,136,137,138,139,140,141],"vertigo and dizziness","Vertebrobasilar Transient Neurological Attack","TIA","Vestibular Symptom","Diagnostic Accuracy","Prognostic Factors","Emergency Department","2026-02-24",{"date":144,"type":40},"2026-02-27",{"date":146,"type":21},"2026-05-01",{"date":148,"type":21},"2028-10",{"name":150,"class":47},"University of Sao Paulo General Hospital",1,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":159,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":151},"100608813","transient-ischemic-attack-tia-and-spoken-language-100608813","NCT07206433","Transient Ischemic Attack (TIA) and Spoken Language","Identification and Perceptions of Spoken Language Abilities After Transient Ischaemic Attack (TIA): An Exploratory, Longitudinal Study","Inclusion Criteria: People aged 40-85 with a diagnosis of a single carotid circulation TIA.\n\nExclusion Criteria:\n\nYounger than 40 years or older than 85 years of age.\n\nEnglish as a secondary language.\n\nNeurological conditions affecting cognitive function (e.g., Parkinson's disease, dementia, stroke).\n\nSelf-reported, pre-existing speech or cognitive problems, developmental or acquired.\n\nDemonstrate noticeable difficulties carrying out project-related tasks.",true,"40 Years","85 Years",{"count":163,"type":21},30,"Transient Ischaemic Attack (also known as TIA or 'mini-stroke') affects about 46,000 people in the UK each year. It is assumed that people recover fully within 24 hours. However, subtle problems with speaking, and confidence with their communication skills can be long-term. This project will be the first in depth exploration of speaking abilities after recent TIA where there seemed to be a full recovery.\n\nThe researchers will look for 90 volunteers for detailed testing. Thirty people who have had a TIA for the first time. For comparisons, the researchers will also include 60 volunteers without TIA (30 treated to prevent TIA and stroke; 30 who do not receive prevention treatments).\n\nAims and methods:\n\n1. To find out if TIA makes speaking difficult.\n\n   People will complete speaking tasks in a quiet place. For example, people will be asked to tell us about their weekend, what they think about climate change.\n2. To find out if people are concerned about their speech and other thinking skills after TIA.\n\n   People will fill in questionnaires to help us look into these issues.\n3. To find out if speaking abilities and people's own views of their communication change over time (about three months after the TIA).\n\nDiscovering new knowledge about spoken communication after a TIA diagnosis could change the course of TIA research and care across health professions (speech-language therapy, psychology, audiology, neurology). Future studies could use speaking tasks to scrutinise further the complexity of subtle communication problems after TIA and determine which individuals are likely to have these problems. The project will raise understanding of these issues, enabling affected individuals to seek professional support. Finally, it will also guide development of new TIA recommendations and treatments for these problems thus improving people's quality of life.",[30],[137,98,167,168],"speech","language","2025-09-25",{"date":171,"type":40},"2025-10-03",{"date":173,"type":21},"2025-10-01",{"date":175,"type":21},"2027-06-30",{"name":177,"class":47},"Newcastle University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":151},"100606350","phase-3-cilostazol-for-prevention-of-recurrent-stroke-trial-100606350","NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial","Clarity","Inclusion Criteria:\n\n* Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days\n* Currently taking aspirin or clopidogrel (not both) to prevent another stroke\n\nExclusion Criteria:\n\n* Had a spontaneous brain bleed within the last 2 years.\n* Moderate to severe heart failure.\n* Life expectancy is less than 6 months.",{"count":186,"type":21},2000,[188],"PHASE3","The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.",[191,192,193,29,30,194,195],"Stroke Recurrence","Myocardial Infarction","Vascular Death","Stroke (CVA) or Transient Ischemic Attack","Recurrent Stroke","2025-09-12",{"date":198,"type":40},"2025-09-16",{"date":200,"type":21},"2026-08",{"date":202,"type":21},"2031-07",{"name":204,"class":47},"Stanford University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":227,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100575649","integrated-approach-in-frail-older-people-with-atrial-fibrillation-100575649","NCT06775028","Integrated Approach in Frail Older People with Atrial Fibrillation","AFFIRMO - Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People","AFFIRMO","Inclusion Criteria:\n\n* Outpatients of both sexes with age ≥65 years;\n* First diagnosed, paroxysmal, persistent, long-standing persistent or permanent AF, confirmed as per guideline-recommended diagnostic criteria for AF, e.g. with electrocardiogram (ECG) or Holter monitoring;\n* ≥1 additional long-term comorbidity, thus fulfilling the definition of multimorbidity: hypertension (treated with at least 2 antihypertensive drugs), coronary artery disease (CAD), peripheral artery disease, heart failure, stroke\u002FTIA, diabetes mellitus, COPD, CKD.\n\nExclusion Criteria:\n\n* Mechanical prosthetic heart valve or moderate\u002Fsevere mitral stenosis;\n* Patient unwilling to be enrolled and sign written informed consent;\n* Patient unable to understand the study and attend the follow-up;\n* Serious diseases with a life expectancy inferior to 12 months;\n* Patients included in other interventional studies.\n\nOnly for sites randomized to the iABC group:\n\n\\- Patient without a device suitable for iABC use.","65 Years",{"count":215,"type":21},1250,[24],"The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities.\n\nThe study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .",[219,220,221,222,223,224,225,226,27,30],"Atrial Fibrillation (AF)","Hypertension","Coronary Arterial Disease (CAD)","Heart Failure","COPD","Peripheral Arterial Disease","CKD","Diabetes Mellitus",[228,229,230],"iABC","Atrial Fibrillation","Cluster Trial","2025-01-09",{"date":233,"type":40},"2025-01-14",{"date":235,"type":40},"2024-04-11",{"date":237,"type":21},"2026-01-31",{"name":239,"class":47},"Heart Care Foundation",50,{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100573966","evaluation-of-the-efficacy-of-novel-biomarkers-in-predicting-clopidogrel-resistance-in-patients-with-ischemic-stroke-100573966","NCT06753149","Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke","Clinical Application Research and Evaluation of Biomarkers Predicting Clopidogrel Resistance in Patients with Ischemic Stroke","Inclusion Criteria:\n\n* Age range: 18-80 years old. Within 72 hours after symptom onset (admission), the patient has started receiving \"standard\" antiplatelet therapy (which must include Plavix, taken alone or in combination)\n* Diagnosed with mild, non cardiogenic, non disabling AIS (NIHSS score ≤ 3) or high-risk TIA (ABCD2 stroke risk assessment ≥ 4) based on the patient's symptoms, signs (such as hemiplegia, hemianopia, hemiparesis, aphasia, etc.) and various routine diagnoses and tests (including but not limited to neuroimaging, such as cranial CT, MRI, Doppler, etc.)\n\nExclusion Criteria:\n\n* 72 hours after the onset of symptoms (admission), the patient began receiving \"standard\" antiplatelet therapy (including polivix, taken alone or in combination) for moderate or severe AIS (NIHSS score ≥ 5)\n* Patients who require intravenous thrombolysis (using rt PA, urokinase, alteplase, or tiniprase, etc.)\n* Mechanical intervention for thrombectomy\n* Cardiogenic AIS (with concomitant atrial fibrillation)\n* Embolic stroke of unknown origin (ESUS)\n* Perioperative stroke\n* Use anticoagulant drugs (such as warfarin, rivaroxaban, dabigatran etexils, etc.)\n* Individuals with severe liver and kidney dysfunction\n* Individuals allergic to clopidogrel or aspirin\n* Individuals with a tendency towards bleeding (such as low platelet count or active gastric or intestinal ulcers)\n* Individuals with a history of easy miscarriage or who are currently pregnant\n* Patients with malignant tumors or life expectancy of less than 1 year","80 Years",{"count":250,"type":21},800,"The goal of this observational study is to explore the potential efficacy of related biomakers in predicting clopidogrel resistance in patients with ischemic stroke. To be specific :\n\n1. To investigate the relationship between the changes in ADP induced platelet aggregation rate, human plasma C4BPα concentration, mRNA expression levels of mARC1 and ABCC3-013 (splicing variant) in peripheral blood leukocytes, and the changes in the mRNA expression levels of ABCC3-013 (splicing variant) in selected hospitalized patients before and on the 3rd and 7th day after antiplatelet therapy, as well as on the 30th and 90th day after follow-up, in accordance with the current guidelines for secondary stroke prevention, and to explore the relative efficacy of each biomarker in predicting clopidogrel resistance;\n2. To collect blood samples from patients, extract their DNA samples, perform CYP2C19 genotyping, validate and evaluate the predictive efficacy and clinical application value of a biomarker \"panel\" composed of multiple new and old biomarkers for predicting clopidogrel resistance.",[29,30,253],"Clopidogrel Resistance","2024-12-23",{"date":256,"type":40},"2024-12-31",{"date":258,"type":21},"2025-02-01",{"date":42,"type":21},{"name":261,"class":47},"Nanjing First Hospital, Nanjing Medical University"]